These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30277131)

  • 1. IL-10 is overexpressed in human cutaneous T-cell lymphoma and is required for maximal tumor growth in a mouse model.
    Wu X; Hsu DK; Wang KH; Huang Y; Mendoza L; Zhou Y; Hwang ST
    Leuk Lymphoma; 2019 May; 60(5):1244-1252. PubMed ID: 30277131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma.
    Ito M; Teshima K; Ikeda S; Kitadate A; Watanabe A; Nara M; Yamashita J; Ohshima K; Sawada K; Tagawa H
    Blood; 2014 Mar; 123(10):1499-511. PubMed ID: 24385540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
    Chang TP; Poltoratsky V; Vancurova I
    J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma.
    Ikeda S; Kitadate A; Ito M; Abe F; Nara M; Watanabe A; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2016 Mar; 7(12):13563-74. PubMed ID: 26789110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
    Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
    Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
    Wang Y; Gu X; Li W; Zhang Q; Zhang C
    J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation.
    Geskin LJ; Viragova S; Stolz DB; Fuschiotti P
    Blood; 2015 Apr; 125(18):2798-805. PubMed ID: 25628470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Small Molecule CCR2 Antagonist Depletes Tumor Macrophages and Synergizes with Anti-PD-1 in a Murine Model of Cutaneous T-Cell Lymphoma (CTCL).
    Wu X; Singh R; Hsu DK; Zhou Y; Yu S; Han D; Shi Z; Huynh M; Campbell JJ; Hwang ST
    J Invest Dermatol; 2020 Jul; 140(7):1390-1400.e4. PubMed ID: 31945344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mast cells play a protumorigenic role in primary cutaneous lymphoma.
    Rabenhorst A; Schlaak M; Heukamp LC; Förster A; Theurich S; von Bergwelt-Baildon M; Büttner R; Kurschat P; Mauch C; Roers A; Hartmann K
    Blood; 2012 Sep; 120(10):2042-54. PubMed ID: 22837530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gallium maltolate inhibits human cutaneous T-cell lymphoma tumor development in mice.
    Wu X; Wang TW; Lessmann GM; Saleh J; Liu X; Chitambar CR; Hwang ST
    J Invest Dermatol; 2015 Mar; 135(3):877-884. PubMed ID: 25371972
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
    JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.
    Wu X; Schulte BC; Zhou Y; Haribhai D; Mackinnon AC; Plaza JA; Williams CB; Hwang ST
    J Invest Dermatol; 2014 Nov; 134(11):2814-2822. PubMed ID: 24780929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genome-wide transcriptome analysis of the STAT6-regulated genes in advanced-stage cutaneous T-cell lymphoma.
    Gaydosik AM; Queen DS; Trager MH; Akilov OE; Geskin LJ; Fuschiotti P
    Blood; 2020 Oct; 136(15):1748-1759. PubMed ID: 32438399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upregulation of inflammatory cytokines and oncogenic signal pathways preceding tumor formation in a murine model of T-cell lymphoma in skin.
    Wu X; Sells RE; Hwang ST
    J Invest Dermatol; 2011 Aug; 131(8):1727-34. PubMed ID: 21490619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
    Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
    Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
    Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
    Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma.
    Mishra A; La Perle K; Kwiatkowski S; Sullivan LA; Sams GH; Johns J; Curphey DP; Wen J; McConnell K; Qi J; Wong H; Russo G; Zhang J; Marcucci G; Bradner JE; Porcu P; Caligiuri MA
    Cancer Discov; 2016 Sep; 6(9):986-1005. PubMed ID: 27422033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
    Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
    J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bu Fei Decoction attenuates the tumor associated macrophage stimulated proliferation, migration, invasion and immunosuppression of non-small cell lung cancer, partially via IL-10 and PD-L1 regulation.
    Pang L; Han S; Jiao Y; Jiang S; He X; Li P
    Int J Oncol; 2017 Jul; 51(1):25-38. PubMed ID: 28534943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.